HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced that it has initiated its previously announced stock repurchase program. On June 15, 2011, Spectrum’s Board of Directors authorized the purchase of up to $25 million of its common stock through the end of 2012.
